TABLE 9

Planned/ongoing phase III randomised controlled trials comparing adjuvant immunotherapy to placebo after complete resection in NSCLC patients

IMpower010 (NCT02486718)ANVIL (NCT02595944)EORTC-ETOP PEARLS trial (NCT02504372)Canadian Cancer Trials Group (NCT02273375)
Experimental armAtezolizumab 1200 mg intravenous 16 cycles every three weeksNivolumab intravenous every two weeks, up to 1 yearPembrolizumab 200 mg intravenous every three weeks up to 1 yearMEDI4736 intravenous up to 1 year
Comparator armobservationobservationplaceboplacebo
EligibilityStage IB (≥4 cm)–IIIA, adjuvant cisplatin based chemotherapyStage IB (≥4 cm)–IIIA, adjuvant cisplatin based chemotherapy tested for PD-L1, EGFR/ALK-Stage IB (≥4 cm)–IIIA, adjuvant cisplatin based chemotherapy tested for PD-L1Stage IB (≥4 cm)–IIIA, ± adjuvant chemotherapy
Primary end-pointDFSDFS, OSDFSDFS in PD-L1+ patients
Secondary end-pointsOS, AEs, pharmacokinetics, immunogenicity1, 2, 5 year DFS and OS, AEs, outcomes according to PD-L1 patterns and mutational loadOS, LCSSDFS in all patients, OS (PD-L1+/all), LCSS (PD-L1+/all), AEs, QoL, cost–utility ratio, pharmacokinetics
Target recruitment845 patients714 patients1380 patients1100 patients
  • PD-L1: programmed death-ligand1; EGFR: epidermal growth factor receptor; ALK: anaplastic lymphoma kinase; DFS: disease-free survival; OS: overall survival; AEs: adverse events; LCSS: lung cancer specific survival.